Cantor Fitzgerald Comments on Disc Medicine FY2025 Earnings

Disc Medicine, Inc. (NASDAQ:IRON) – Analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Disc Medicine in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska expects that the company will post earnings per share of ($5.24) for the year. Cantor Fitzgerald has a “Overweight” rating and a $85.00 price objective on the stock. The consensus estimate for Disc Medicine’s current full-year earnings is ($4.07) per share.

Disc Medicine (NASDAQ:IRON) last issued its earnings results on Tuesday, November 12th. The company reported ($0.89) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.04) by $0.15.

Several other brokerages also recently issued reports on IRON. Morgan Stanley raised Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 target price on the stock in a research note on Tuesday, November 5th. Wedbush reaffirmed an “outperform” rating and issued a $90.00 price objective (up previously from $83.00) on shares of Disc Medicine in a research note on Tuesday. Raymond James raised Disc Medicine from an “outperform” rating to a “strong-buy” rating and lifted their price objective for the stock from $66.00 to $110.00 in a research note on Monday, November 4th. Jefferies Financial Group began coverage on Disc Medicine in a research note on Wednesday, October 23rd. They issued a “buy” rating and a $89.00 price objective on the stock. Finally, Stifel Nicolaus lifted their price objective on Disc Medicine from $79.00 to $90.00 and gave the stock a “buy” rating in a research note on Tuesday, December 10th. Nine analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $88.50.

Disc Medicine Trading Down 3.3 %

Shares of IRON opened at $58.50 on Wednesday. The business’s 50 day moving average is $62.73 and its 200 day moving average is $53.69. The company has a market capitalization of $1.74 billion, a PE ratio of -14.70 and a beta of 0.75. Disc Medicine has a 12-month low of $25.60 and a 12-month high of $77.60.

Insider Activity at Disc Medicine

In other Disc Medicine news, insider Rahul Khara sold 7,500 shares of the company’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $62.75, for a total value of $470,625.00. Following the completion of the sale, the insider now directly owns 14,035 shares in the company, valued at approximately $880,696.25. This represents a 34.83 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider William Jacob Savage sold 9,158 shares of the business’s stock in a transaction on Friday, November 15th. The stock was sold at an average price of $59.64, for a total value of $546,183.12. Following the completion of the transaction, the insider now directly owns 40,405 shares of the company’s stock, valued at approximately $2,409,754.20. The trade was a 18.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 85,758 shares of company stock worth $5,400,990 in the last quarter. 4.24% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Wellington Management Group LLP increased its position in Disc Medicine by 4.8% during the 3rd quarter. Wellington Management Group LLP now owns 1,840,226 shares of the company’s stock valued at $90,429,000 after buying an additional 83,731 shares in the last quarter. Frazier Life Sciences Management L.P. increased its position in Disc Medicine by 123.5% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 1,754,834 shares of the company’s stock valued at $79,090,000 after buying an additional 969,834 shares in the last quarter. Deerfield Management Company L.P. Series C increased its position in Disc Medicine by 53.8% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 1,023,265 shares of the company’s stock valued at $46,119,000 after buying an additional 357,730 shares in the last quarter. Logos Global Management LP acquired a new position in Disc Medicine during the 2nd quarter valued at about $41,690,000. Finally, State Street Corp increased its position in Disc Medicine by 39.7% during the 3rd quarter. State Street Corp now owns 827,910 shares of the company’s stock valued at $40,683,000 after buying an additional 235,115 shares in the last quarter. 83.70% of the stock is owned by institutional investors.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.